COLL news

Latest 2 stories · newest Nov 5, 2026

COLL

Collegium Reports Q3 2026 Results; Reaffirms Full-Year 2026 Guidance

Collegium Pharmaceutical reported a record $216.3 million in quarterly net revenues, fueled by a 24% year-over-year increase in JORNAY PM sales. The company also reiterated its 2026 financial outlook and announced a $50 million share repurchase program to deploy capital into shareholder value.

Earnings Nov 5, 2026 sentiment +0.60 SEC filing ↗

COLL

Collegium reports Q2 2026 performance and completes AZSTARYS acquisition

Quarterly revenues increased to $199.9 million, driven by 41% YoY growth in JORNAY PM as the company integrates its recently acquired ADHD portfolio.

M&A Aug 6, 2026 sentiment +0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same COLL feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/COLL/newsSTART FREE